Using AI-Analysis Tools And A Next-Generation High-Content Screening Platform To Improve 3D Screening Assay Data Capturing

By Zhisong Tong, Angeline Lim, Jayne Hesley, Matt Chan, Tim Baranowski, Oksana Sirenko, Misha Bashkurov, and Andy Bashford, Molecular Devices

This content is brought to you by Molecular Devices, a Danaher Operating Company.

Image-based high-content screening (HCS) is a powerful strategy in drug discovery that evaluates drug effects by quantifying image-based features to describe cellular changes within or among cell populations. As interest in 3D biological models grows, there is a rising demand for an imaging platform that not only captures high-throughput, high-quality images in 3D samples but also facilitates complex image analysis.

Introducing the next generation in high-content imaging: the ImageXpress® HCS.ai High-Content Screening System by Molecular Devices. This advanced system is equipped with flexible confocal spinning disk options, modular hardware, and a modern, intuitive software interface. Designed for greater precision and speed, the new imager leverages state-of-the-art optics with an enhanced signal-to-noise ratio. These combined improvements in acquisition speed, image quality, and machine learning-assisted analysis enable the use of a broader range of assays and models for both research and 3D drug screening.

Access the full poster to learn more.